213 related articles for article (PubMed ID: 28755323)
1. Detection of the alternative lengthening of telomeres pathway in malignant gliomas for improved molecular diagnosis.
Fogli A; Demattei MV; Corset L; Vaurs-Barrière C; Chautard E; Biau J; Kémény JL; Godfraind C; Pereira B; Khalil T; Grandin N; Arnaud P; Charbonneau M; Verrelle P
J Neurooncol; 2017 Nov; 135(2):381-390. PubMed ID: 28755323
[TBL] [Abstract][Full Text] [Related]
2. The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas.
Grandin N; Pereira B; Cohen C; Billard P; Dehais C; Carpentier C; Idbaih A; Bielle F; Ducray F; Figarella-Branger D; Delattre JY; Sanson M; Lomonte P; Poncet D; Verrelle P; Charbonneau M;
Acta Neuropathol Commun; 2019 Nov; 7(1):175. PubMed ID: 31706351
[TBL] [Abstract][Full Text] [Related]
3. Molecular Characteristics of Thalamic Gliomas in Adults.
Wang T; Niu X; Gao T; Zheng L; Qiu Y; Mao Q
J Mol Neurosci; 2021 Aug; 71(8):1598-1604. PubMed ID: 33523385
[TBL] [Abstract][Full Text] [Related]
4. Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma.
Mukherjee J; Johannessen TC; Ohba S; Chow TT; Jones L; Pandita A; Pieper RO
Cancer Res; 2018 Jun; 78(11):2966-2977. PubMed ID: 29545335
[TBL] [Abstract][Full Text] [Related]
5. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
[TBL] [Abstract][Full Text] [Related]
6. Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas.
Yi L; Fan X; Li J; Yuan F; Zhao J; Nistér M; Yang X
Aging (Albany NY); 2021 Jan; 13(3):3645-3660. PubMed ID: 33493139
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
[TBL] [Abstract][Full Text] [Related]
8. Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study.
Ang SYL; Lee L; See AAQ; Ang TY; Ang BT; King NKK
BMC Cancer; 2020 Jan; 20(1):79. PubMed ID: 32005184
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral Susceptibility Signals Reflect Biomarker Status in Gliomas.
Kong LW; Chen J; Zhao H; Yao K; Fang SY; Wang Z; Wang YY; Li SW
Sci Rep; 2019 Nov; 9(1):17080. PubMed ID: 31745161
[TBL] [Abstract][Full Text] [Related]
10. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
[TBL] [Abstract][Full Text] [Related]
11. Potential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure control.
Feyissa AM; Worrell GA; Tatum WO; Chaichana KL; Jentoft ME; Guerrero Cazares H; Ertekin-Taner N; Rosenfeld SS; ReFaey K; Quinones-Hinojosa A
Seizure; 2019 Jul; 69():283-289. PubMed ID: 31141785
[TBL] [Abstract][Full Text] [Related]
12. In Vivo Molecular Profiling of Human Glioma : Cross-Sectional Observational Study Using Dynamic Susceptibility Contrast Magnetic Resonance Perfusion Imaging.
Hempel JM; Schittenhelm J; Klose U; Bender B; Bier G; Skardelly M; Tabatabai G; Castaneda Vega S; Ernemann U; Brendle C
Clin Neuroradiol; 2019 Sep; 29(3):479-491. PubMed ID: 29468261
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and outcomes of elderly patients with diffuse gliomas: a multi-institutional cohort study by Kansai Molecular Diagnosis Network for CNS Tumors.
Sasaki T; Fukai J; Kodama Y; Hirose T; Okita Y; Moriuchi S; Nonaka M; Tsuyuguchi N; Terakawa Y; Uda T; Tomogane Y; Kinoshita M; Nishida N; Izumoto S; Nakajima Y; Arita H; Ishibashi K; Shofuda T; Kanematsu D; Yoshioka E; Mano M; Fujita K; Uematsu Y; Nakao N; Mori K; Kanemura Y
J Neurooncol; 2018 Nov; 140(2):329-339. PubMed ID: 30076584
[TBL] [Abstract][Full Text] [Related]
14. Tumor location and patient age predict biological signatures of high-grade gliomas.
Altieri R; Zenga F; Ducati A; Melcarne A; Cofano F; Mammi M; Di Perna G; Savastano R; Garbossa D
Neurosurg Rev; 2018 Apr; 41(2):599-604. PubMed ID: 28856492
[TBL] [Abstract][Full Text] [Related]
15. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age.
Lötsch D; Ghanim B; Laaber M; Wurm G; Weis S; Lenz S; Webersinke G; Pichler J; Berger W; Spiegl-Kreinecker S
Neuro Oncol; 2013 Apr; 15(4):423-32. PubMed ID: 23393205
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation mediated up-regulation of TERRA non-coding RNA is coincident with elongated telomeres in the human placenta.
Novakovic B; Napier CE; Vryer R; Dimitriadis E; Manuelpillai U; Sharkey A; Craig JM; Reddel RR; Saffery R
Mol Hum Reprod; 2016 Nov; 22(11):791-799. PubMed ID: 27604461
[TBL] [Abstract][Full Text] [Related]
18. Clinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas.
Siegal T
Adv Tech Stand Neurosurg; 2016; (43):91-108. PubMed ID: 26508407
[TBL] [Abstract][Full Text] [Related]
19. Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas.
Haberler C; Wöhrer A
Clin Neuropathol; 2014; 33(2):108-11. PubMed ID: 24559763
[TBL] [Abstract][Full Text] [Related]
20. ATRX immunostaining predicts IDH and H3F3A status in gliomas.
Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J
Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]